Additional efficacy results from RELATIVITY-047 evaluating the fixed-dose combination of relatlimab and nivolumab vs. Opdivo monotherapy in previously untreated metastatic or unresectable melanoma.
validation enforced?
CHECKPOINT INHIBITORS - What The?, page-9
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.8¢ |
Change
0.008(2.03%) |
Mkt cap ! $559.2M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $968.9K | 2.543M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 88484 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 38003 | 28 |
View Market Depth
| Last trade - 12.48pm 28/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |